# Novartis Is Largely Abandoning Ionis Heart Drug After Trial Failure

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/52121
Published: 2026-11-09T06:58:02.000Z
Updated: 2026-11-09T06:58:02.000Z
Section: Business

> The RNA-targeting candidate failed in a late-stage trial last September.

Novartis is largely abandoning development of a heart disease treatment discovered by Ionis Pharmaceuticals after the RNA-targeting candidate failed in a late-stage trial last September.

Ionis discovered the candidate, which targets RNA. Novartis had been developing it for heart disease.